These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 19441871)
21. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. Rockstroh JK; DeJesus E; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Plummer A; Abram M; Cheng AK; Fordyce MW; Szwarcberg J; J Acquir Immune Defic Syndr; 2013 Apr; 62(5):483-6. PubMed ID: 23337366 [TBL] [Abstract][Full Text] [Related]
22. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K; Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936 [TBL] [Abstract][Full Text] [Related]
23. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens. Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439 [TBL] [Abstract][Full Text] [Related]
24. Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730. González-García J; Cohen D; Johnson M; Sloan L; Fredrick L; Naylor C; da Silva B; Bernstein B; AIDS Res Hum Retroviruses; 2010 Aug; 26(8):841-5. PubMed ID: 20672994 [TBL] [Abstract][Full Text] [Related]
25. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A; J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529 [TBL] [Abstract][Full Text] [Related]
26. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240 [TBL] [Abstract][Full Text] [Related]
27. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Sax PE; Wohl D; Yin MT; Post F; DeJesus E; Saag M; Pozniak A; Thompson M; Podzamczer D; Molina JM; Oka S; Koenig E; Trottier B; Andrade-Villanueva J; Crofoot G; Custodio JM; Plummer A; Zhong L; Cao H; Martin H; Callebaut C; Cheng AK; Fordyce MW; McCallister S; Lancet; 2015 Jun; 385(9987):2606-15. PubMed ID: 25890673 [TBL] [Abstract][Full Text] [Related]
28. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. Rockstroh JK; DeJesus E; Lennox JL; Yazdanpanah Y; Saag MS; Wan H; Rodgers AJ; Walker ML; Miller M; DiNubile MJ; Nguyen BY; Teppler H; Leavitt R; Sklar P; J Acquir Immune Defic Syndr; 2013 May; 63(1):77-85. PubMed ID: 23412015 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Daar ES; DeJesus E; Ruane P; Crofoot G; Oguchi G; Creticos C; Rockstroh JK; Molina JM; Koenig E; Liu YP; Custodio J; Andreatta K; Graham H; Cheng A; Martin H; Quirk E Lancet HIV; 2018 Jul; 5(7):e347-e356. PubMed ID: 29925490 [TBL] [Abstract][Full Text] [Related]
30. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients. Kulkarni R; Abram ME; McColl DJ; Barnes T; Fordyce MW; Szwarcberg J; Cheng AK; Miller MD; White KL HIV Clin Trials; 2014; 15(5):218-30. PubMed ID: 25350960 [TBL] [Abstract][Full Text] [Related]
31. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Fung HB; Stone EA; Piacenti FJ Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284 [TBL] [Abstract][Full Text] [Related]
32. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml. Nishijima T; Komatsu H; Teruya K; Tanuma J; Tsukada K; Gatanaga H; Kikuchi Y; Oka S AIDS; 2013 Mar; 27(5):839-42. PubMed ID: 23719354 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily. Elion R; Cohen C; Ward D; Ruane P; Ortiz R; Reddy YS; Ebrahimi R; McColl D; Kearney B; Fisher A; Flaherty J; HIV Clin Trials; 2008; 9(4):213-24. PubMed ID: 18753116 [TBL] [Abstract][Full Text] [Related]
34. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK; N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366 [TBL] [Abstract][Full Text] [Related]
35. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF; AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091 [TBL] [Abstract][Full Text] [Related]
36. Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection. Moyle GJ; Hardy H; Farajallah A; DeGrosky M; McGrath D Clin Drug Investig; 2014 Apr; 34(4):287-96. PubMed ID: 24557728 [TBL] [Abstract][Full Text] [Related]
37. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Martorell CT; de Wet J; Stellbrink HJ; Molina JM; Post FA; Valero IP; Porter D; Liu Y; Cheng A; Quirk E; SenGupta D; Cao H Lancet HIV; 2017 May; 4(5):e205-e213. PubMed ID: 28259776 [TBL] [Abstract][Full Text] [Related]
38. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097 [TBL] [Abstract][Full Text] [Related]
39. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data. Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918 [TBL] [Abstract][Full Text] [Related]
40. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection. Deeks ED Drugs; 2018 Jul; 78(10):1013-1024. PubMed ID: 29915897 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]